(Q40389829)

English

Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

David B. Weiner

10

object named as

David B Weiner

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Michele A Kutzler

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Chuanhai Cao

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Yun Bai

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Huiqin Dong

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Philip Y Choe

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Vera Saulino

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Laura McLaughlin

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Alex Whelan

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Andrew Y Choo

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Kenneth E Ugen

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

24 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

4630-4639

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Mechanisms of neuronal degeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Humoral Immune Response to Fibrillar β-Amyloid Peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Generation of anti-beta-amyloid antibodies via phage display technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.036

7 January 2021

Identifiers

10.1016/J.VACCINE.2005.08.036

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40389829&oldid=2086913733"